| Revenue growth | 16.2% YoY growth in revenue from operations |
|---|---|
| Margins | EBITDA margin softened to 19.3% from 22.2% YoY |
| Demand visibility | Strong footfall at Dombivli; healthy occupancy in established hospitals |
| Management confidence | High; citing steady occupancy ramp-up and insurance empanelment |
Growth
Revenue grew to Rs 411 Cr (up 16.4% YoY); EBITDA remained stable at Rs 79.3 Cr despite initial ramp-up losses.
Outlook
Scaling capacity from 1,700 to 2,900 beds via greenfield projects in Pune, Mira Road, and BKC.
Risks
EBITDA impacted by Rs 9.5 Cr Dombivli loss; higher interest and depreciation from ongoing expansion.
Last quarter's promises, checked
Delivered
- Dombivli commissioning by Q1 FY27 → delivered Feb 2026 (= BEAT)
- Dombivli EBITDA burn INR 2-3 Cr/month → delivered INR 3.1 Cr/month (= BEAT)
- Asset-heavy model capex ~INR 1.5 Cr/bed → delivered ~INR 1.5 Cr/bed (= BEAT)
Partly delivered
- Dombivli insurance empanelment 6-12 months → delivered ongoing Q1FY27 (= PARTIAL)
Investor Presentation filed with BSE, NSE: JLHL. Summary written with AI assistance from the document.
Jupiter Life Line Hospitals Ltd: key numbers
- Share price
- ₹248.55
- Market cap
- ₹8,148 Cr
- Revenue (annual)
- ₹1,500 Cr
- Net profit (annual)
- ₹194.0 Cr
- P/E (TTM)
- 43.4×Sector 53.1×
- Promoter holding
- 40.91%+0.00% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jupiter Life Line Hospitals Ltd
All →Jupiter Life Line Hospitals Earnings Call Transcript: Key Takeaways
Management is optimistic as the new Dombivli hospital ramps up, despite it causing a 9.5 crore EBITDA drag this quarter.
Jupiter Life Line Hospitals Other Announcement
Jupiter Life Line Hospitals Limited has authorized specific Key Managerial Personnel for determining and disclosing material events under SEBI Regulation 30(5).
Jupiter Life Line Hospitals Management Change
Jupiter Life Line Hospitals Limited has appointed Mr. Harshad Gaurishankar Purani as the new Chief Financial Officer, effective July 31, 2026.
Jupiter Life Line Hospitals Merger & Restructuring Worth ₹3.78 Cr
Jupiter Life Line Hospitals' subsidiary, Jupiter Hospital Pharmacy, acquired 100% of Sulcus Private Limited for ₹3.78 Crore. This move aims to expand pharmaceutical manufacturing capabilities.
- Value
- ₹3.78 Cr
Jupiter Life Line Hospitals Q1 FY27 Results: Net Profit ₹37.5 Cr, Down 14.6% YoY
Jupiter Life Line Hospitals Ltd reported revenue from operations of ₹411 Cr (+16.4% YoY) and net profit of ₹37.5 Cr (-14.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹37.5 Cr · -14.6% YoY
Jupiter Life Line Hospitals Share Pledge
Catalyst Trusteeship Ltd disclosed the creation of a pledge over 1,67,59,750 equity shares of Jupiter Life Line Hospitals Ltd.